PFEON
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Nome da cripto PFEON
Classificação No.1352
Capitalização de mercado $0.00
Capitalização de mercado totalmente diluída $0.00
Market share %
Vol. de negociação/Capitalização de mercado (24h) 617.20%
Fornecimento circulante 119,587.21703893
Fornecimento máximo 0
Fornecimento total 119,587.21703893
Taxa circulante %
Data de emissão --
O preço quando o ativo foi emitido pela primeira vez --
Máximo histórico 29.905065233816003, 2026-06-07
Menor preço 23.881609665406096, 2025-09-25
Blockchain pública PFEON
Apresentação Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Setor
Midias sociais
Análise de entrada de fundos
|
Comprar(PFEON) |
Vender(PFEON) |
Entrada líquida |
| Grande |
0.000 |
6.209K |
-6208.580 |
| Média |
0.000 |
0.000 |
0.000 |
| Pequena |
6.720K |
520.320 |
6.200K |
| Total |
6.720K |
6.729K |
-8.830 |
etfindex:mc_etfindex_source Isenção de responsabilidade: Os dados fornecidos por cmc e não devem ser considerados como conselhos de investimento.
